In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on Vericel (VCEL – Research Report). The company’s shares closed yesterday at $58.08.
Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and TransMedics Group. According to TipRanks, Jennings has an average return of 9.6% and a 53.32% success rate on recommended stocks.
Vericel has an analyst consensus of Strong Buy, with a price target consensus of $63.57.
VCEL market cap is currently $2.84B and has a P/E ratio of 921.76.
Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VCEL in relation to earlier this year. Last month, Paul Wotton, a Director at VCEL sold 2,600.00 shares for a total of $152,672.00.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vericel (VCEL) Company Description:
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
